Evidence map›Paper›PMID 32542442›Full record

ArticleEJNMMI research2020

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo.

Sheng Zhao, Wenbin Pan, Huijie Jiang, Rongjun Zhang, Hao Jiang, Zonghui Liang, Hongbo Hu

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Radioimmunotherapy study ofEJNMMI research · 2022
    Article
  2. Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sheng ZhaoDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wenbin PanDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Huijie JiangDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. jianghuijie@hrbmu.edu.cn.ORCID http://orcid.org/0000-0002-8356-9643
Rongjun ZhangJiangsu Institute of Nuclear Medicine, Wuxi, China. zhangrongjun@jsinm.org.
Hao JiangDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zonghui LiangJing'an District Centre Hospital of Shanghai, Fudan University, Shanghai, China. liangzhjhj@163.com.
Hongbo HuDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Harbin Medical University · CNJiangsu Second Normal University · CNJinshan Hospital of Fudan University · CN

Funding

National Key Scientific Instrument and Equipment Development Projects of China (CN) No.2019YFC0118100National Natural Science Foundation of China No.81671760, 81873910National Natural Science Foundation of China No.81871423Scientific Research Project of Health and Family Planning Commission of Heilong jiang Province No. 201622 and 201812Scientific Research Transformation Special Fund of Heilongjiang Academy of Medical Sciences No.2018415
6 · The paper itself

Abstract

backgroundPreclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in the tumors. A

methodAnti-PD-L1 monoclonal antibody labeled with

results

conclusionsThere is a great potential for

Indexed as

Cerenkov luminescence imagingColorectal cancerImmunotherapyPreclinical toolProgrammed death ligand-1

Identifiers

PMID32542442
PMCPMC7295871
OpenAlexW3035395288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.